anti-CD19/CD20/CD22/CD30 CAR-T cells
Term · Oncology and biomedicine · MLC-T-ONC-010272
A preparation of human T lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19), CD20, CD22 and CD30, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD19/CD20/CD22/CD30 CAR-T cells target and bind to CD19, CD20, CD22 and CD30 expressed on the surface of certain tumor cells. This induces selective toxicity in tumor cells expressing these TAAs. The TAAs are overexpressed in certain hematologic malignancies.
| Identifier | MLC-T-ONC-010272 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | anti-CD19/CD20/CD22/CD30 chimeric antigen receptor-T cells; CAR-T CD19/CD20/CD22/CD30 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-010272",
"term": "anti-CD19/CD20/CD22/CD30 CAR-T cells",
"field": "Oncology and biomedicine",
"definition": "A preparation of human T lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19), CD20, CD22 and CD30, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD19/CD20/CD22/CD30 CAR-T cells target and bind to CD19, CD20, CD22 and CD30 expressed on the surface of certain tumor cells. This induces selective toxicity in tumor cells expressing these TAAs. The TAAs are overexpressed in certain hematologic malignancies.",
"synonyms": [
"anti-CD19/CD20/CD22/CD30 chimeric antigen receptor-T cells",
"CAR-T CD19/CD20/CD22/CD30"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/anti-cd19-cd20-cd22-cd30-car-t-cells/"
}
Record 1,358 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.